Industry Spotlight  |
Proteins & Antibodies

Delays for New COVID Drugs

Edited by Tia Byer |
17 June 2022
Clinical studies testing treatments for severe COVID-19 face major delays due to eligibility issues.

The heroic efforts of scientists and researchers in their fight against the global COVID pandemic of 2020 and 2021 will go down in history. But now, there seems to be a shortage of eligible patients for the latest round of clinical trials.

The success of the global inoculation roll-out has raised fears that developing new treatment options for severe COVID-19 could fail as the ability to organise clinical trials to test them becomes increasingly challenging.

Reasons behind reported delays can be linked to the vaccinations’ triumph in decreasing severe disease response and the patient population for further study. Resistance to enrol in patient trials is evident, and the statistical analysis accompanying the delivery of potent drug treatments poses further difficulties.

Currently, Doctors and health practitioners have the availability of approximately six different treatment options for COVID. World Health Organisation (WHO) and US Food and Drug Administration (FDA) have approved therapies such as synthetic antibodies, steroids, and antiviral tablets, to name a few.

An unforeseen drawback and complication of the welcome inoculation success is the evident shrinking of eligible patient pools.

Whilst death rates are falling, there remains a need to unlock the next generation of treatments. In particular, widespread distribution of antiviral therapy to lower-income countries could prevent the majority of COVID-related death and hospitalisations. However, many treatments are expensive and are limited in supply.

An unforeseen drawback and complication of the welcome inoculation success is the evident shrinking of eligible patient pools. Trials to develop future COVID treatments are being stalled by the lack of patient populations now being infected with severe cases of the virus.

As it becomes more and more challenging to recruit patient participants, researchers and scientists alike must look for new and innovative ways to start addressing the future need for next-generation COVID treatments.

Join us for Vaccines Europe: In-Person happening 29 – 30 November 2022 in Berlin, Germany to take part in an intensive 2-day in person meeting that delves into the latest in vaccine research, platform technologies, analytics and vaccine development. For more information visit Oxford Global.     

Share this article

Share on facebook
Share on twitter
Share on linkedin

Sign up for our monthly Biologics Newsletter

You may also be interested in...

Industry Spotlight
Hot off the press, we look at this week’s breaking news stories from the Biologics industry.
22 June 2022
Industry Spotlight
Researchers from ETH Zurich demonstrate the promise of deep learning for predicting antigen specificity.
03 June 2022

Continue browsing

Share this article

Share on facebook
Share on twitter
Share on linkedin

Join our Biologics mailing list

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Member Community Login

Stay up to date

Sign up for our monthly Editorial Newsletter to keep up with all things Biologics